Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant

Trakarnvanich, Thananda; Ngamvitchukorn, T.; Phumisantiphong, Uraporn; Pholtawornkulchai, Kittisak; Phochanasomboon, Krittima; Manomaipiboon, Anan

doi:10.1016/j.vaccine.2022.09.067

Cited by 15 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could result in fewer B cells recruited into the primary response and yield stunted antibody responses, similar to what is observed in patients treated with B-cell depletion therapies [38]. However, our data show that subsequent recall humoral responses are largely preserved in HD patients, compared to equivalent controls, similar to that observed by others [19, [39][40][41]. This suggests that, although primary B cell responses may be different in HD patients, germinal centres can form and produce memory B cells that can respond upon subsequent antigen challenge, both in the context of vaccination and infection.…”

Section: Discussionsupporting

confidence: 90%

Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients

Wall,

Lamerton,

Ashford

et al. 2024

Preprint

View full text Add to dashboard Cite

Generalised immune dysfunction in chronic kidney disease, especially in patients requiring haemodialysis (HD), significantly enhances the risk of severe infections. Moreover, vaccine-induced immunity is typically reduced in HD populations, but the full mechanisms behind this remain unclear. The SARS-CoV-2 pandemic provided an opportunity to examine the magnitude and functionality of antibody responses in HD patients to a previously unencountered antigen, Spike (S)-glycoprotein, after vaccination with different vaccine platforms (viral vector (VV); mRNA (mRV)). Here, we compared total and functional anti-S antibody responses (cross-variant neutralisation and complement binding) in 187 HD patients and 43 healthy controls 21-28 days after serial immunisation. After 2 doses of the same vaccine, HD patients had anti-S antibody levels and complement binding capacity comparable to controls. However, 2 doses of mRV induced greater polyfunctional antibody responses than VV, yet previous SARS-CoV-2 infection or an mRV boost after 2 doses of VV significantly enhanced antibody functionality in HD patients. Therefore, HD patients can generate near-normal, functional antigen-specific antibody responses following serial vaccination to a novel antigen, suggesting largely intact B cell memory. Encouragingly, exploiting immunological memory by using mRNA vaccines and boosting may improve the success of vaccination strategies in this vulnerable patient population.

show abstract

Section: Discussionsupporting

confidence: 90%

Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients

Wall,

Lamerton,

Ashford

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, neutralizing Ab rise was also significantly higher in AstraZeneca primed individuals compared to Sinopharm recipients. In agreement with us, blood group O was associated with better immunological responses in a study on Thai cases who got adenovirus‐based vaccine 23 . On the contrary, an investigation in Spanish population showed no differences between the blood groups regarding Ab titer after BNT162b2 vaccine 24 .…”

Section: Discussionsupporting

confidence: 84%

“…In agreement with us, blood group O was associated with better immunological responses in a study on Thai cases who got adenovirus-based vaccine. 23 On the contrary, an investigation in Spanish population showed no differences between the blood groups regarding Ab titer after BNT162b2 vaccine. 24 Hence, blood type could be a potential immune enhancer with some vaccine platforms.…”

Section: Discussionmentioning

confidence: 94%

The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID‐19 vaccine regimens

Sadat Larijani,

Javadi,

Eskandari

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

This study evaluated the possible effects of blood types on coronavirus disease (COVID‐19) vaccine immunogenicity and antibody (Ab) persistency. Five different vaccinated groups against COVID‐19 were investigated at Pasteur Institute of Iran from April 2021 to December 2022. Anti‐Spike IgG and neutralizing Ab rise were tracked on Day 21 as well as the humoral immune persistency assessment 180 after booster shots. Late adverse events up to 6 months after the booster dose were collected. The results showed that blood type A, led to a significantly higher anti‐Spike Ab rise in AstraZeneca primed recipients in comparison with Sinopharm primed ones in heterologous regimens (p: 0.019). Furthermore, blood type O was a great co‐effector in homologous AstraZeneca recipients regarding neutralizing Ab rise (0.013). In addition, blood type O led to a better anti‐Spike Ab persistency in the Sinopharm homologous group whereas type A had the best effect on neutralizing Ab durability in the same vaccine group. What is more, Rh‐positive individuals in AstraZeneca + PastoCovac Plus group had a higher rate of anti‐Spike Ab rise (p = 0.001). Neutralizing Ab rise was also induced in AstraZeneca homologous and heterologous regimens of Rh‐positive individuals significantly higher than Sinopharm primed cases. The present study showed the potential impact of blood types A/O and Rh‐positive on a better humoral immune responses and Ab persistency. It is proposed that blood type A and Rh‐positive could increase the Ab rise in AstraZeneca vaccinated individuals. Moreover, blood type O might be a better co‐effector of anti‐Spike Ab persistency in Sinopharm recipients.

show abstract

“…Most studies used mRNA vaccines for immunization, with limited reports on other vaccination mechanisms, such as inactivated viruses or viral vectors. These studies indicated a slight disadvantage in achieving seroconversion in individuals with CKD compared to those who received mRNA vaccines [93][94][95]. Additionally, administering different types of vaccines in a heterologous regimen has been found to increase immune response compared to homologous regimens, as observed in a study of patients undergoing HD [96,97].…”

Section: Emerging Treatments Of Covid-19 In Ckd Patientsmentioning

confidence: 89%

COVID-19 and Chronic Kidney Disease: A Narrative Review

Martins,

de Oliveira

2023

COVID

View full text Add to dashboard Cite

The coronavirus disease-2019 (COVID-19) pandemic has had a profound impact on the world, causing loss of life, economic damage, and social disruption. Individuals with chronic kidney disease (CKD) are prone to complications and increased mortality related to COVID-19. Efforts have been made to increase understanding of the effects of COVID-19 in individuals with CKD. This paper aims to gather and discuss the state-of-the-art in the COVID-19 and CKD literature, involving the early history of COVID-19, the immunological aspects of CKD (such as abnormalities in neutrophilicand dendritic cells functions), the mechanisms of kidney injury by SARS-CoV-2 (for example, viral tropism to kidney tissue and direct cytotoxicity), the clinical course of the disease and consequences for CKD individuals (including kidney transplant recipients), and the emerging treatments (such as the use of Remdesivir, nirmatrelvir, and monoclonal neutralizing antibodies) and immunization for the CKD population.

show abstract

Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant

Cited by 15 publications

References 42 publications

Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients

Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients

The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID‐19 vaccine regimens

COVID-19 and Chronic Kidney Disease: A Narrative Review

Contact Info

Product

Resources

About